

# Veröffentlichungen

1. **S. Zielen**, P. Devillier, J. Heinrich, H. Richter, U. Wahn. Sublingual immunotherapy provides long-term relief in allergic rhinitis and reduces the risk of asthma: A retrospective, real-world database analysis. *Allergy*. 2017
2. J. Trischler, A. Lieb, M. Arnold, J. Schulze, M. Rosewich, R. Schubert, I. Bottoli, **S. Zielen**. Omalizumab effectively protects against early and late allergic responses in asthma after 4 weeks. *Allergy*. 2017.
3. Koppitz M, Eschenburg C, Salzmann E, Rosewich M, Schubert R, **Zielen S**. Mucolytic Effectiveness of Tyloxapol in Chronic Obstructive Pulmonary Disease - A Double-Blind, Randomized Controlled Trial. *PLoS One*. 2016 16;11(6).
4. **Zielen S**, Trischler J, Schubert R. Lipopolysaccharide challenge: immunological effects and safety in humans. *Expert Rev Clin Immunol*. 2015;11(3):409-18.
5. Schroeder SA, **Zielen S**. Infections of the respiratory system in patients with ataxia-telangiectasia. *Pediatr Pulmonol*. 2014; 49(4):389-99.
6. Rosewich M, Lee D, **Zielen S**. Pollinex Quattro: an innovative four injections immunotherapy in allergic rhinitis. *Hum Vaccin Immunother*. 2013;9(7):1523-31.
7. Rosewich M, Arendt S, El Moussaoui S, Schulze J, Schubert R, **Zielen S**. Bronchial allergen provocation: a useful method to assess the efficacy of specific immunotherapy in children. *Pediatr Allergy Immunol*. 2013;24(5):434-40.
8. **Zielen S**, Lieb A, De La Motte S, et al. Omalizumab protects against allergen-induced bronchoconstriction in allergic (immunoglobulin E-mediated) asthma. *Int Arch Allergy Immunol*. 2013;160(1):102-10.
9. **Zielen S**, Kardos P, Madonini E. Steroid-sparing effects with allergen-specific immunotherapy in children with asthma: a randomized controlled trial. *J Allergy Clin Immunol*. 2010; 126(5):942-9.
10. **Zielen S**, Christmann M, Kloska M, et al. Predicting short term response to anti-inflammatory therapy in young children with asthma. *Curr Med Res Opin*. 2010; 26(2):483-92.